Office-based methadone VS buprenorphine to address retention in medication for opioid use disorder (moud)-a pragmatic hybrid effectiveness/implementation trial (CTN-013). 09/28/2022 - 08/04/2025.…
Active Awarded Last action
- Contract number
- 75N95022F00003
- Awardee
-
The Emmes Company, LLC UEI NBQCBJ6FXBU4
- Awarding agency
-
National Institute on Drug Abuse
National Institutes of Health, Department of Health and Human Services
- Obligated
- $1,861,518
Award facts
- Opportunity
-
- Data, Statistics, and Clinical Trial Support Center (DSC6) Pre-Solicitation · 75N95022F00003 · Posted Nov 10, 2021
- Contract value 100% obligated
- $1,861,518.00 Current and potential, with all options
- Completion date 94% complete
- Current and potential, with all options
- NAICS code
- 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Cost Plus Fixed Fee
- Place of performance
- Rockville, MD 20850, USA
- Legislative mandates
-
- Service Contract Act FAR subpart 22.10
- Employment Eligibility Verification (E-Verify) FAR subpart 22.18
- Service Contract Inventory FAR subpart 4.17
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Supplemental Agreement for work within scope | $0 | |
| Exercise an Option | $834,665 | |
| Original award | $1,026,853 |
About this award
This federal contract award, identified as 75N95022F00003 (TO3), was issued by the National Institute on Drug Abuse (NIDA) to The Emmes Company LLC, a global clinical research organization. The contract is part of the NIDA Data, Statistics, and Clinical Trial Support Center and supports an "Office-Based Methadone vs Buprenorphine to Address Retention in Medication for Opioid Use Disorder (MOUD)-A Pragmatic Hybrid Effectiveness/Implementation Trial (CTN-013)" project. The period of performance is from September 28, 2022, to January 31, 2027, with a ceiling value of $1,861,518.00. This is a cost-plus-fixed-fee delivery order contract with no set-aside designation. The Emmes Company LLC has a long history of providing comprehensive research support services to NIDA and other federal agencies within the National Institutes of Health.
Description
Office-based methadone VS buprenorphine to address retention in medication for opioid use disorder (moud)-a pragmatic hybrid effectiveness/implementation trial (CTN-013). 09/28/2022 - 08/04/2025. DSC6. 75N95022F00003 (TO3).
Quick answers
Who was awarded contract 75N95022F00003?
75N95022F00003 was awarded to The Emmes Company, LLC by National Institute on Drug Abuse (National Institutes of Health) on September 28, 2022.
How much is contract 75N95022F00003 worth?
The government has obligated $1,861,518 on 75N95022F00003.
Is contract 75N95022F00003 an order under another contract?
Yes. 75N95022F00003 is a delivery order under 75N95022D00017, an indefinite delivery contract.
Was contract 75N95022F00003 competed?
The extent of competition for 75N95022F00003 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award